Brought to you by

Janssen partners with Alector on Alzheimer's drug candidate
31 Mar 2014
Executive Summary
Janssen Pharmaceuticals Inc., in tandem with Johnson & Johnson’s Innovation Center in California, agreed to fund research of an Alector LLC (focused on treatments for Alzheimer’s disease and other forms of dementia) target for AD through proof-of-concept.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com